75岁以上老年多发性骨髓瘤85例临床特点和疗效分析

Clinical characteristics and analysis of multiple myeloma in patients over 75 years old

目的分析75岁以上老年多发性骨髓瘤(MM)患者的临床特点和疗效。方法对北京大学人民医院1996年8月至2015年4月所有75岁以上MM患者85例临床资料进行回顾性分析。结果 85例老年MM患者平均年龄为(78.5±3.78)岁,DS分期Ⅲ期52例、R-ISS分期Ⅲ期5例。接受治疗的70例患者中,治疗方案中含硼替佐米29例,不含硼替佐米41例。含硼替佐米与不含硼替佐米的治疗相比,对75岁以上老年患者治疗有效率、无进展生存(PFS)期、总生存(OS)期差异均无统计学意义。结论 75岁以上老年MM患者为虚弱状态,虚弱比例达87%,含硼替佐米方案无明显有效率、PFS及OS获益。

Objective This study aimed to analysis clinical features and efficacy of multiple myeloma in patients over 75 years old. Methods we retrospectively analyzed 85 cases of multiple myeloma over 75 years old,who were diagnosed from August 1996 to April 2015 in Peking University People＇s hospital. Results the mean age was （78.5±3.78）years, and the median age was 77 years. There were 52 cases in DS stage III, and 5 cases in R-ISS stage III. 70 cases received treatment, among them, 29 cases received bortezomib containing regimens, 41 cases received regimens without bortezomib. In multiple myeloma patients of over 75 years old, there was no significant difference in treatment efficacy, progression-free survival and overall survival. Conclusion patients over 75 years old with multiple myeloma were frailty, frail patients were 87%, there were no benefit of efficacy3 PFS and OS on bortezomib-containing regimens.